Compare JOUT & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOUT | RLMD |
|---|---|---|
| Founded | 1970 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 456.3M | 524.9M |
| IPO Year | 1994 | 2012 |
| Metric | JOUT | RLMD |
|---|---|---|
| Price | $46.91 | $5.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.40 |
| AVG Volume (30 Days) | 33.6K | ★ 1.6M |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | N/A | ★ 45.28 |
| EPS | N/A | N/A |
| Revenue | ★ $592,415,000.00 | $13,070.00 |
| Revenue This Year | $11.67 | N/A |
| Revenue Next Year | $3.70 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 154.83 |
| 52 Week Low | $34.69 | $0.55 |
| 52 Week High | $53.54 | $8.00 |
| Indicator | JOUT | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 51.27 | 35.17 |
| Support Level | $43.00 | $4.85 |
| Resistance Level | $48.02 | $7.28 |
| Average True Range (ATR) | 1.31 | 0.39 |
| MACD | 0.14 | -0.01 |
| Stochastic Oscillator | 49.28 | 13.01 |
Johnson Outdoors Inc is a manufacturer and marketer of branded seasonal, outdoor recreation products used for fishing from a boat, diving, paddling, hiking and camping. The company has four operating segment: Fishing, Camping, Watercraft Recreation, and Diving. It generates maximum revenue from the Fishing segment which produces and markets products under different brands such as Minn Kota electric motors for quiet trolling or primary propulsion, marine battery chargers and shallow water anchors; Humminbird sonar and GPS equipment for fish finding, navigation and marine cartography; and Cannon downriggers for controlled-depth fishing. Geographically, it derives a majority of revenue from the United States and also has a presence in Europe, Canada, and other regions.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.